UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
ý |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2002
OR
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 0-28701
HealthGate Data Corp.
(Exact name of registrant as specified in its charter)
Delaware | 04-3220927 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
25 Corporate Drive, Suite 310, Burlington, Massachusetts |
01803 |
|
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (781) 685-4000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. Yes ý No o
The number of shares outstanding of the registrant's common stock as of July 22, 2002 was 6,014,676.
HealthGate Data Corp.
FORM 10-Q
For the Quarter Ended June 30, 2002
INDEX
|
|
Page |
||
---|---|---|---|---|
PART I. FINANCIAL INFORMATION | ||||
Item 1. |
Financial Statements |
|||
Condensed Consolidated Balance Sheets at June 30, 2002 (unaudited) and December 31, 2001 |
3 |
|||
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2002 and 2001 (unaudited) |
4 |
|||
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2002 and 2001 (unaudited) |
5 |
|||
Notes to Condensed Consolidated Financial Statements |
6 |
|||
Item 2. |
Management's Discussion and Analysis of Financial Condition and Results of Operations |
11 |
||
Item 3. |
Quantitative and Qualitative Disclosures about Market Risk |
27 |
||
PART II. OTHER INFORMATION |
||||
Item 4. |
Submission of Matters to a Vote of Security Holders |
28 |
||
Item 6. |
Exhibits and Reports on Form 8-K |
28 |
||
Signatures |
29 |
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
HEALTHGATE DATA CORP.
CONDENSED CONSOLIDATED BALANCE SHEET
|
June 30, 2002 |
December 31, 2001 |
|||||||
---|---|---|---|---|---|---|---|---|---|
|
(unaudited) |
|
|||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 5,569,544 | $ | 8,588,708 | |||||
Accounts receivable, including receivables from related parties of $0 and $7,250 at June 30, 2002 and December 31, 2001, respectively, and net of allowance for doubtful accounts $9,050 and $20,740 at June 30, 2002 and December 31, 2001, respectively | 183,924 | 43,622 | |||||||
Prepaid expenses and other current assets | 511,487 | 324,921 | |||||||
Total current assets | 6,264,955 | 9,357,251 | |||||||
Fixed assets, net | 2,575,767 | 3,492,271 | |||||||
Marketing and distribution rights, net | 239,104 | 597,736 | |||||||
Other assets | 764,085 | 322,260 | |||||||
Total assets | $ | 9,843,911 | $ | 13,769,518 | |||||
Liabilities and Stockholders' Equity | |||||||||
Current liabilities: | |||||||||
Current portion of capital lease obligation | $ | 83,639 | $ | 213,733 | |||||
Accounts payable | 909,726 | 1,001,232 | |||||||
Accrued expenses | 1,656,688 | 1,925,798 | |||||||
Deferred revenue | 2,743,727 | 3,555,234 | |||||||
Total current liabilities | 5,393,780 | 6,695,997 | |||||||
Long-term portion of capital lease obligation | | 5,823 | |||||||
Other long-term liabilities | 1,160,561 | 1,425,435 | |||||||
Total liabilities | 6,554,341 | 8,127,255 | |||||||
Stockholders' equity: | |||||||||
Common stock, $.03 par value; Authorized: 100,000,000 shares Issued and outstanding: 6,014,676 shares at June 30, 2002 and December 31, 2001 | 180,440 | 180,440 | |||||||
Additional paid in capital | 99,202,276 | 99,202,276 | |||||||
Accumulated deficit | (96,093,146 | ) | (93,730,988 | ) | |||||
Deferred compensation | | (9,465 | ) | ||||||
Total stockholders' equity | 3,289,570 | 5,642,263 | |||||||
Commitments and contingencies (Notes 4 and 6) | | | |||||||
Total liabilities and stockholders' equity | $ | 9,843,911 | $ | 13,769,518 | |||||
The accompanying notes are an integral part of these financial statements.
3
HEALTHGATE DATA CORP.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(unaudited)
|
Three Months Ended June 30, 2002 |
Three Months Ended June 30, 2001 |
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue, including revenue from related parties of $0 and $709,311 for the three months ended June 30, 2002 and 2001, respectively and $115,583 and $1,764,220 for the six months ended June 30, 2002 and 2001, respectively | $ | 1,503,261 | $ | 2,253,297 | $ | 3,145,272 | $ | 5,021,947 | |||||||
Costs and expenses: | |||||||||||||||
Cost of revenue | 740,515 | 837,867 | 1,213,560 | 1,626,025 | |||||||||||
Research and development | 605,067 | 774,534 | 1,304,765 | 1,690,904 | |||||||||||
Sales and marketing | 388,349 | 2,458,855 | 897,868 | 4,281,005 | |||||||||||
General and administrative | 1,098,436 | 1,607,602 | 2,214,872 | 3,249,413 | |||||||||||
Total costs and expenses | 2,832,367 | 5,678,858 | 5,631,065 | 10,847,347 | |||||||||||
Loss from operations | $ | (1,329,106 | ) | $ | (3,425,561 | ) | $ | (2,485,793 | ) | $ | (5,825,400 | ) | |||
Interest and other income, net |
82,742 |
107,961 |
123,635 |
276,976 |
|||||||||||
Net loss | $ | (1,246,364 | ) | $ | (3,317,600 | ) | $ | (2,362,158 | ) | $ | (5,548,424 | ) | |||
Basic and diluted net loss per share |
$ |
(0.21 |
) |
$ |
(0.55 |
) |
$ |
(0.39 |
) |
$ |
(0.93 |
) |
|||
Shares used in computing basic and diluted net loss per share |
6,014,676 |
5,999,441 |
6,014,676 |
5,997,067 |
The accompanying notes are an integral part of these financial statements.
4
HEALTHGATE DATA CORP.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
Increase (Decrease) in Cash and Cash Equivalents
(unaudited)
|
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|||||||
---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | $ | (2,362,158 | ) | $ | (5,548,424 | ) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | 1,436,605 | 1,807,076 | |||||||
Stock based compensation | 9,465 | 76,737 | |||||||
Loss on sales of fixed assets | | 22,958 | |||||||
Changes in assets and liabilities: | |||||||||
Accounts receivable | 259,698 | 1,976,749 | |||||||
Prepaid expenses and other current assets | (186,566 | ) | 115,326 | ||||||
Other assets | (93,833 | ) | (118,760 | ) | |||||
Accounts payable | (91,506 | ) | (1,542,753 | ) | |||||
Accrued expenses | (269,110 | ) | (259,208 | ) | |||||
Deferred revenue | (811,507 | ) | (257,408 | ) | |||||
Other long-term liabilities | (264,874 | ) | | ||||||
Net cash used in operating activities | (2,373,786 | ) | (3,727,707 | ) | |||||
Cash flows from investing activities: | |||||||||
Proceeds from sales and maturities of marketable securities | | 4,931,061 | |||||||
Purchases of fixed assets | | (113,058 | ) | ||||||
Acquisition of assets of TNP | (393,200 | ) | | ||||||
Expenditures for capitalized software | (116,261 | ) | (428,116 | ) | |||||
Refund on purchase of fixed assets | | 247,735 | |||||||
Net cash provided by (used in) investing activities | (509,461 | ) | 4,637,622 | ||||||
Cash flows from financing activities: | |||||||||
Payment of capital lease obligation | (135,917 | ) | (157,049 | ) | |||||
Proceeds from issuance of common stock | | 6,085 | |||||||
Net cash used in financing activities | (135,917 | ) | (150,964 | ) | |||||
Net increase (decrease) in cash and cash equivalents | (3,019,164 | ) | 758,951 | ||||||
Cash and cash equivalents, beginning of period | 8,588,708 | 4,594,167 | |||||||
Cash and cash equivalents, end of period | $ | 5,569,544 | $ | 5,353,118 | |||||
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | $ | 15,000 | $ | 40,000 |
The accompanying notes are an integral part of these financial statements.
5
HEALTHGATE DATA CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation and Financial Condition
HealthGate Data Corp. ("HealthGate" or the "Company") is a provider and electronic publisher of healthcare information to healthcare institutions, corporations and government agencies for professionals, patients, and consumers. HealthGate currently provides access to this content on an individual resource basis to customers that prefer to choose specific content elements. HealthGate also provides its CHOICE products which consist of content and related services on a pre-packaged basis. The Company's XML-based content can be delivered electronically to its customers or built into clinical software systems.
HealthGate has recently developed additional proprietary content including information that is tagged using the most popular medical coding vocabularies. The Company anticipates marketing this content to healthcare institutions and related healthcare organizations for use in a variety of clinical systems. In 2002, HealthGate was an early adopter of Microsoft's.NET XML services platform which enables applications to communicate and share data regardless of operating system, device, or programming language. During the second quarter, HealthGate began development of HealthGate OnSite which will enable customers to download HealthGate's content files and host them on their own servers.
HealthGate's consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the continuity of business, realization of assets and the satisfaction of liabilities in the ordinary course of business. At June 30, 2002, the Company had $5,570,000 of cash and cash equivalents, and $871,000 of working capital. The Company has incurred substantial losses and negative cash flows from operations in every fiscal year since inception. For the six months ended June 30, 2002, the Company incurred a net loss of $2,362,000 and negative cash flows from operations of $2,374,000. Additionally as of June 30, 2002, the Company had an accumulated deficit of $96,093,000.
The Company has taken numerous actions to substantially reduce operating cash outflows. These actions included workforce reductions, terminating the Company's agreement with NBC Internet, Inc. ("NBCi"), and amending or canceling several content arrangements. Many of these cost savings were made possible through process improvements, development of proprietary content and focusing on content sales and service. If the Company does not achieve its forecasted revenue levels in the future, management is prepared to implement additional cost reductions.
Based on HealthGate's forecasted cash flows and its cash and cash equivalents on hand, the Company expects to have sufficient cash to finance its operations for at least the next twelve months. The Company's future beyond the next twelve months is dependent upon its ability to achieve break-even or positive cash flow, or raise additional financing. There can be no assurances that the Company will be able to do so.
HealthGate is subject to risks and uncertainties common to technology-based companies, including rapid technological developments, reliance on continued development and acceptance of the Internet, intense competition and a limited operating history.
The accompanying unaudited condensed consolidated interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements, and should be read in conjunction with the audited financial statements included in HealthGate's Form 10-K for the year ended December 31, 2001. However, in the opinion of management, the accompanying interim financial statements have been prepared on the same basis as
6
the audited financial statements, and include all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full fiscal year or any future period. Certain amounts in the prior period condensed consolidated financial statements have been reclassified to conform to the current period presentation.
2. Net Loss Per Share
Net loss per share is computed in accordance with Statement of Financial Accounting Standards No. 128, "Earnings Per Share" ("SFAS 128"). Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding. Diluted net loss per share does not differ from basic net loss per share since potential common shares from exercise of stock options and warrants are anti-dilutive for all periods presented. As of June 30, 2002, options to purchase 249,816 shares of the Company's stock and warrants to purchase 1,110,279 shares of the Company's common stock were outstanding.
3. Revenue Recognition
HealthGate primarily derives revenue from licensing access to its content repository and other content services, including Web site development and hosting arrangements such as CHOICE® Web sites. In 2002, HealthGate began entering into publishing agreements with print publishers. HealthGate has also generated revenue from activePress services and online advertising, sponsorships and e-commerce, including user subscription and transaction based fees.
HealthGate records revenue in accordance with Staff Accounting Bulletin No. 101 ("SAB 101"). Revenue from services arrangements is recognized ratably over the terms of the underlying agreement between HealthGate, the customer, and if applicable, HealthGate's authorized reseller, which generally ranges from one to three years. HealthGate typically does business with its customers using standard contracts and does not begin to recognize revenue until such contract is signed by both parties. For any arrangement in which HealthGate guarantees advertising commissions to the customer, HealthGate records fees paid by the customer as a customer deposit, up to the amount of the applicable guarantee. Payments made to customers under these guarantees are recorded as reductions of the related customer deposit. The excess of the fee paid by the customer to HealthGate over guaranteed advertising and sponsorship commissions, if any, is recognized as revenue ratably over the term of the underlying agreement. For those arrangements in which HealthGate guarantees advertising and sponsorship commissions in excess of the fees paid by the customer, the excess is recorded as expense upon signing the agreement. For arrangements in which HealthGate sells through a reseller, HealthGate does not recognize any revenue until an agreement has been finalized between HealthGate, its customer, and its authorized reseller, and the content has been delivered. Revenue is not recognized in any circumstances unless collectability is deemed probable.
If consideration, including equity instruments, is given to a customer or reseller for which the Company does not receive a separate identifiable benefit with a determinable fair value, the Company characterizes the recognition of such consideration as a reduction in revenue, to the extent there is cumulative revenue from such customer or reseller. Any excess recognition of such consideration is recorded as a expense.
7
Revenue from licensing electronic content to print publishers for print distribution, including minimum royalties, is recognized upon delivery of the content as long HealthGate has no material future obligations.
HealthGate rarely enters into multi-element service arrangements. When HealthGate does enter into such an arrangement, each element is accounted for separately over its respective service period, provided that there is objective evidence of fair value, such as the price charged for each element when sold separately. If the fair value of each element cannot be objectively determined, the total value of the arrangement is recognized ratably over the entire service period. For all multi-element service arrangements to date, the fair value of each element has not been objectively determinable. Therefore, all revenue under these contracts has been recognized ratably over the related service period. For arrangements under which HealthGate receives equity instruments in exchange for services, HeathGate determines the value of the arrangement based on the fair value of the equity received or services provided, whichever is more readily determinable.
4. Lease Exit Costs
HealthGate leases approximately 32,000 square feet of office space under a lease, which expires in June 2005. HealthGate's annual cost for this space is at a rate of approximately $28 per square foot per year. During the fourth quarter of 2001, the Company committed to an exit plan to vacate approximately 20,000 square feet of excess space at its headquarters building. HealthGate finalized a sublease for a portion of this excess space in February 2002.
HealthGate's results of operations for the year ended December 31, 2001 included a charge of $1,880,000 as a result of these activities. This charge represents accrual of expenses relating to HealthGate's continued liability under its lease and is included in liabilities on HealthGate's balance sheet at December 31, 2001. The activity for the six months ended June 30, 2002 relating to this accrual are as follows:
Payments | $ | (367,308 | ) | |
Payments received from tenant | 89,026 | |||
Depreciation on leasehold improvements | (21,545 | ) | ||
Liability at June 30, 2002 | 1,579,901 | |||
Less: current portion |
(419,340 |
) |
||
Other long-term liabilities | $ | 1,160,561 | ||
The charge and accrual included certain significant estimates and assumptions which will be monitored for changes in facts and circumstances. It is reasonably possible that changes in circumstances and evaluation of assumptions may require adjustment to this charge in future periods, and the amount could be material.
5. Acquisition
On February 12, 2002, HealthGate acquired, from Random House, Inc., the assets of The Natural Pharmacist ("TNP"), a publisher of comprehensive evidence-based alternative and natural health content for consumers and healthcare professionals. The total purchase price of $393,000 consisted of
8
$350,000 in cash and $43,000 in direct transactional costs. In accordance with the provisions of Statement of Financial Accounting Standards No. 141, the purchase price was allocated to the assets acquired based on their value at the date of acquisition, with $48,000 of the purchase price being allocated to accounts receivable and $345,000 allocated to purchased content. This purchased content asset is being amortized on a straight-line basis over the estimated three-year life of the underlying asset. The pro forma effect of this acquisition in the three and six months ended June 30, 2001 and 2002 would not have been significant.
6. Other Commitments and Contingencies
HealthGate has entered into agreements to license content for its services from various unrelated third parties. Future minimum license payments under these agreements as of June 30, 2002 totaled approximately $564,000.
In July 1999, HealthGate received a letter alleging that HealthGate's Web site induces users to infringe a patent held by a company (the "Holder"). In lieu of pursuing a patent infringement claim against HealthGate, the Holder offered to provide HealthGate with a license for unlimited use of the patent for a one-time payment of between $50,000 and $150,000. There has been no recent activity on this matter and at this time, HealthGate is unable to predict its outcome.
From time to time HealthGate becomes subject to legal proceedings and claims arising in connection with its business. HealthGate does not believe that there were any asserted claims at June 30, 2002 that, if adversely decided, would have a material adverse effect on its results of operations, financial condition or liquidity.
7. Related Party Transactions
Through the Company's activePress service, HealthGate was the developer on the Web of a collection of approximately 320 full text journals for Blackwell Science. The Company's agreement with Blackwell Science, as amended, expired in January 2002. HealthGate's results of operations for the six months ended June 30, 2002 and 2001 include $116,000 and $926,000 of revenue relating to this agreement. HealthGate does not expect to have significant revenues from Blackwell Science for the remainder of 2002. Blackwell Science is a principal stockholder of HealthGate.
In June 1999, HealthGate entered into a development and distribution agreement with GE Medical Systems ("GEMS"). The agreement, as amended, runs through June 2003. Under the terms of this agreement, GEMS may sell HealthGate's standard CHOICE product and GEMS' branded enhanced versions of HealthGate's CHOICE product through its worldwide sales force into its worldwide customer base of hospitals and other patient care facilities. HealthGate's results of operations for the three and six months ended June 30, 2002 include no revenue from GEMS. HealthGate's results of operations for the three and six months ended June 30, 2001 include $397,000 and $839,000, respectively of revenue from GEMS.
In October 1999, HealthGate entered into a three-year strategic alliance agreement with Snap! LLC and Xoom.com, Inc. The rights of Snap! LLC and Xoom.com, Inc. were subsequently assigned to NBCi. Under the original agreement, NBCi was to provide various services to promote HealthGate's name, the www.healthgate.com Web site, enterprise-based CHOICE Web sites and the products and services HealthGate offers. In exchange for the services provided to HealthGate by NBCi during the
9
first year of the agreement, HealthGate issued to NBCi 166,666 shares of its common stock in November 1999. In January 2000, HealthGate paid NBCi a minimum cash fee of $10,000,000 plus a $250,000 production and content integration fee. In September 2000, HealthGate amended this agreement. One of the provisions of the revised agreement was that HealthGate agreed to redirect its user traffic from www.healthgate.com to the Health Channel section of NBCi's consumer Internal portal at www.nbci.com so that NBCi could count all user traffic as part of its total user base.
In March 2001, HealthGate further amended its agreement with NBCi. Under the amended agreement, HealthGate issued a warrant to purchase 66,666 shares of HealthGate common stock at $0.5625 per share, the then current market price of HealthGate's stock. The Company ascribed a value of approximately $38,000 to the warrant, which was recorded as prepaid advertising and was being amortized over the remaining term of the amended agreement. HealthGate was also to pay NBCi $2,100,000 in cash in 2001 and $2,800,000 in cash in 2002, and was to provide content to NBCi through October 2004. In return, NBCi was to feature HealthGate as the anchor tenant on the men's health, women's health and drugs and medications sections of the Health Channel of the NBCi portal through October 2002 and share advertising and sponsorship revenue derived from the co-branded www.healthgate.nbci.com Web site with HealthGate through October 2004.
In June 2001, HealthGate negotiated to end its contract with NBCi. In connection with this termination agreement HealthGate paid NBCi $831,000 during the third quarter of 2001. HealthGate also paid $592,000 in 2001 under the March 2001 amended agreement.
NBCi is wholly owned by National Broadcasting Company, a subsidiary of General Electric Company. General Electric Company is a principal stockholder of HealthGate.
8. Research and Development and Software Development Costs
Costs incurred in the research and development of HealthGate's products are expensed as incurred, except for certain software development costs. In accordance with the American Institute of Certified Public Accountants' Statement of Position 98-1, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use" ("SOP 98-1"), HealthGate capitalizes costs incurred during the application development stage of software developed for internal use. During the three and six months ended June 30, 2002 development costs totaling $51,000 and $116,000, respectively, were capitalized. These costs will be amortized to cost of revenue on a straight-line basis over the expected one-year life of the related software, once the software is complete and ready for its intended use.
Costs incurred in the research and development of HealthGate's content and products, except for certain software development costs as described above, are expensed as incurred. The cost to develop proprietary content and update existing content is expensed as research and development costs in the period the costs are incurred.
10
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
This report on Form 10-Q contains certain statements that are forward-looking and actual results may differ materially from those contemplated by the forward-looking statements. These forward-looking statements reflect management's current expectations, are based on many assumptions and are subject to certain risks and uncertainties. Factors that might cause or contribute to such differences are described further below and in the periodic reports and registration statements HealthGate files from time to time with the Securities and Exchange Commission, including HealthGate's most recent Form 10-K. Investors are cautioned not to place undue reliance on the forward-looking statements, which appear elsewhere in this report on Form 10-Q. HealthGate does not intend to update or publicly release any revisions to the forward-looking statements.
Overview
HealthGate Data Corp. ("HealthGate" or the "Company") is a market-leading provider and electronic publisher of healthcare information. HealthGate offers customers a comprehensive content repository of healthcare information. HealthGate's authoritative content has been chosen by more than 600 hospitals in the United States to provide the capability to drive down costs through clinician and patient education, more effective research, improved treatment and regulatory compliance. The Company's XML-based content can be delivered electronically to its customers or built into clinical software systems.
On February 12, 2002, HealthGate acquired from Random House, Inc. the assets of The Natural Pharmacist ("TNP"), a publisher of comprehensive evidenced-based alternative and natural health content for consumers and healthcare professionals. HealthGate paid approximately $393,000, consisting of $350,000 in cash and approximately $43,000 in direct transactional costs, to acquire the assets of TNP, consisting primarily of complementary and alternative health content and trademarks. HealthGate has applied the purchase accounting provisions of Statement of Financial Accounting Standards No. 141, "Business Combinations" ("SFAS 141") in recording this transaction. See Note 5 to the financial statements.
HealthGate's management believes it has developed a scalable and sustainable business model. The Company's limited operating history makes an evaluation of the business and its prospects difficult. Investors should not use the Company's past results as a basis to predict future performance. The Company intends to continue to invest in its content repository. The Company plans to manage its expenses in line with its revenue growth. However, HealthGate cannot assure investors that it will achieve significant revenue or profitability or, if significant revenue or profitability is achieved, that the Company will be able to sustain them.
At June 30, 2002, the Company had $5,570,000 of cash and cash equivalents and $871,000 of working capital. The Company has incurred substantial losses and negative cash flows from operations in every fiscal year since inception. In the six months ended June 30, 2002, the Company incurred a net loss of $2,362,000 and negative cash flows from operations of $2,374,000. Additionally, as of June 30, 2002, the Company had an accumulated deficit of $96,093,000.
The Company has taken numerous actions to substantially reduce operating cash outflows. These actions included workforce reductions, terminating the Company's agreement with NBC, Internet, Inc. ("NBCi"), and amending or canceling several content arrangements. If the Company does not achieve its forecasted revenue levels in the future, management is prepared to implement additional cost reductions.
Based on HealthGate's forecasted cash flows and its cash and cash equivalents on hand, the Company expects to have sufficient cash to finance its operations for at least the next twelve months.
11
The Company's future beyond the next twelve months is dependent upon its ability to achieve break-even or positive cash flow, or raise additional financing. There can be no assurances that the Company will be able to do so.
Critical Accounting Policies and Significant Judgments and Estimates
HealthGate's discussion and analysis of its financial condition and results of operations are based upon HealthGate's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. HealthGate evaluates its estimates on an on-going basis. HealthGate bases its estimates on assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
A complete description of critical accounting policies and significant judgments used in the preparation of HealthGate's consolidated financial statements can be found in the Company's most recent Form 10-K. The following critical accounting policies and significant judgments and estimates represent selected updates to those disclosed in the Form 10-K.
Revenue Recognition. HealthGate primarily derives revenue from licensing access to its content repository and other content services, including Web site development and hosting arrangements such as CHOICE® Web sites. In 2002, HealthGate also began entering into publishing agreements with print publishers. HealthGate has also generated revenue from providing activePress services, online advertising, sponsorships and e-commerce, including user subscription and transaction based fees. In order to focus on being a provider and electronic publisher of healthcare information, HealthGate chose to phase out its advertising, sponsorship and e-commerce offerings in November 2000. Accordingly, there is limited revenue from these activities in 2001. HealthGate's activePress agreement with Blackwell Science terminated in January 2002. HealthGate no longer provides activePress services.
HealthGate records revenue in accordance with Staff Accounting Bulletin No. 101 ("SAB 101"). Revenue from services arrangements is recognized ratably over the terms of the underlying agreement between HealthGate, the customer, and if applicable, HealthGate's authorized reseller, which generally ranges from one to three years. HealthGate typically does business with its customers using standard contracts and does not begin to recognize revenue until such contract is signed by both parties. For any arrangement in which HealthGate guarantees advertising commissions to the customer, HealthGate records fees paid by the customer as a customer deposit, up to the amount of the applicable guarantee. Payments made to customers under these guarantees are recorded as reductions of the related customer deposit. The excess of the fee paid by the customer to HealthGate over guaranteed advertising and sponsorship commissions, if any, is recognized as revenue ratably over the term of the underlying agreement. For those arrangements in which HealthGate guarantees advertising and sponsorship commissions in excess of the fees paid by the customer, the excess is recorded as expense upon signing the agreement. For arrangements in which HealthGate sells through a reseller, HealthGate does not recognize any revenue until an agreement has been finalized between HealthGate, its customer, and its authorized reseller, and the content has been delivered. Revenue is not recognized under any circumstances unless collectability is deemed probable.
Effective January 1, 2002, HealthGate adopted Emerging Issues Task Force Issue No. 01-09, "Accounting for Consideration Given by a Vendor to a Customer" ("EITF 01-09"). EITF 01-09 addresses whether a vendor should recognize consideration given to a customer as an expense or as an
12
offset to revenue being recognized from that same customer. Consideration given to a customer is presumed to be a reduction in revenue unless both of the following conditions are met:
If both conditions are met, consideration paid to the customer may be recognized as expense.
Upon adopting EITF 01-09, HealthGate reviewed its agreements with both vendor and customer components that might be impacted. As a result, HealthGate has reclassified $179,000 of amortization of marketing and distribution rights relating to the warrant issued to CIS Holdings, Inc. in November 1999 from expense to a reduction in revenue for each of the three months ended June 30, 2002 and 2001 and reclassified amortization of $359,000 relating to this warrant for each of the six months ended June 30, 2002 and 2001 from expense to a reduction in revenue. Identifying transactions that are within the scope of EITF 01-09, and determining whether those transactions meet the criteria for recognition as expense, requires HealthGate to make significant judgments. If HealthGate reached different conclusions, reported revenues could be materially different.
In November 1999, HealthGate entered into a three year development agreement with Columbia Information Systems, Inc., now known as HCA-Information Technology & Services, Inc. ("HCA-Information"), a subsidiary of HCA, Inc., formerly known as Columbia/HCA Healthcare Corporation ("HCA"), to design, develop and maintain customized, co-branded CHOICE Web sites for up to 280 HCA hospitals and affiliates. The agreement provided for an annual license fee of $3,500,000 to be paid by HCA-Information for all products and services that HealthGate provides under the agreement. The agreement could be terminated without cause by HCA-Information on June 1, 2001, upon payment of a $1,000,000 termination fee to HealthGate. HealthGate began delivering customized co-branded CHOICE Web sites pursuant to this agreement in December 1999.
In March 2001, HealthGate and HCA-Information amended the development agreement. The term of the amended agreement is from March 2001 to November 2002 and calls for HCA-Information to pay license fees to HealthGate of approximately $1,417,000 in both 2001 and 2002. The amendment significantly reduced the content that will be made available on the customized HCA-Information CHOICE Web sites, increased the maximum number of hospitals covered to 330 and eliminated HCA-Information's option to terminate the Agreement on June 1, 2001. The annual license fees from this agreement are recognized ratably over the term of the amended agreement. As of June 30, 2002, the Company had delivered 287 customized co-branded CHOICE Web sites to HCA hospitals.
Revenue from licensing electronic content to print publishers for print distribution, including minimum royalties, is recognized upon delivery of the content as long HealthGate has no material future obligations.
E-commerce revenue has been derived principally from individual user online subscriptions and from transaction fees for the fee based access to portions of the HealthGate Web sites. Revenue from user subscriptions is recognized ratably over the subscription period, and revenue from transactional based fees is recognized when the related service is provided.
HealthGate rarely enters into multi-element service arrangements. When HealthGate does enter into such an arrangement, each element is accounted for separately over its respective service period, provided that there is objective evidence of fair value, such as the price charged for each element when sold separately. If the fair value of each element cannot be objectively determined, the total value of the arrangement is recognized ratably over the entire service period. For all multi-element service
13
arrangements to date, the fair value of each element has not been objectively determinable. Therefore all revenue under these contracts has been recognized ratably over the related service period.
Software Development and Content Development Costs. Costs incurred in the research and development of HealthGate's products are expensed as incurred, except for certain software development costs. In accordance with the American Institute of Certified Public Accountants' Statement of Position 98-1, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use" ("SOP 98-1"), HealthGate capitalizes certain costs, primarily internal labor, incurred during the application development stage of software developed for internal use. These costs are amortized to cost of revenue on a straight-line basis over the expected one-year life of the related software, once the software is complete and ready for its intended purpose. During the six months ended June 30, 2002, $116,000 of software development costs were capitalized. During the three months ended March 31, 2002 $66,000 of software development costs were capitalized relating to HealthGate's Project Intellect initiative. HealthGate began amortizing these expenses to cost of revenue in April 2002. During the three months ended June 30, 2002, HealthGate capitalized $50,000 of software development costs related to a new development project. HealthGate expects to capitalize additional software development costs during the remainder of 2002. HealthGate has made a significant judgment in estimating the useful life of the capitalized software to be one year. Operating results would be materially different if a different useful life were used.
Costs incurred in the research and development of HealthGate's content and products, except for certain software development costs as described above, are expensed as incurred. The cost to develop proprietary content and update existing content is expensed as research and development costs in the period the costs are incurred. Operating results would be materially different if such costs were capitalized and amortized over the expected benefit period.
Marketing and Distribution Rights. In June 1999, HealthGate entered into a development and distribution agreement with GE Medical Systems ("GEMS"), an affiliate of a General Electric Company. Under the terms of this agreement, GEMS may sell HealthGate's standard CHOICE product and GEMS' branded enhanced versions of HealthGate's CHOICE product through its worldwide sales force into its worldwide customer base of hospitals and other patient care facilities. In connection with this agreement, HealthGate issued a warrant to General Electric Company for the purchase of up to 396,600 shares of HealthGate's common stock. The warrant has a term of five years, was immediately exercisable and had an original exercise price of $28.47 per share, which exercise price was adjusted to $10.38 per share on January 1, 2000. The fair value of this warrant was determined to be $10,300,000 at the time of issuance using the Black-Scholes option pricing model, based on the following assumptions: 100% volatility, a term of 5 years, and an interest rate of 5.6%. This amount was recorded as marketing and distribution rights, and was amortized on a straight-line basis over the one year contractual term of the related development and distribution agreement. In connection with the exercise price adjustment to $10.38 per share on January 1, 2000, the value of the marketing and distribution rights increased by approximately $1,243,000. This incremental value was amortized over the remaining term of the development and distribution agreement. The warrant was fully amortized in 2000.
In November 1999, HealthGate entered into a three-year marketing and reseller agreement with Columbia Information Systems, Inc., now known as HCA-Information Technology & Services, Inc. ("HCA-Information"), a subsidiary of HCA, Inc., formerly known as Columbia/HCA Healthcare Corporation ("HCA"), under which HCA-Information agreed to endorse HealthGate as the preferred provider of patient and consumer oriented health content for Web sites owned or operated by HCA hospitals and affiliates. The agreement provides HealthGate, among other things, the right to make a first offer to provide services for adding content to the HCA-Information's health portal site and any site owned or operated by or affiliated with HCA-Information or HCA. Further, HCA-Information may, for a commission, market and sell HealthGate's CHOICE products to entities unaffiliated with
14
HCA, subject to HealthGate's approval. In connection with this agreement HealthGate issued a warrant to CIS Holdings, Inc., an affiliate of HCA and HCA-Information, for the purchase of up to 647,012 shares of HealthGate's common stock. The warrant has a term of three years, an exercise price per share of $33.00 and became exercisable in January 2000 upon HealthGate's initial public offering. The fair value of this warrant was determined to be $13,500,000 using the Black-Scholes option pricing model, based on the following assumptions: 100% volatility, a term of 3 years, and an interest rate of 6.6%. This amount was recorded as marketing and distribution rights, and is being amortized on a straight-line basis over the three-year contractual term of the related agreement.
When issued, HealthGate concluded that it was appropriate to record the value of the warrants as assets and amortize the assets over the contractual term of the related agreements rather than record one-time charges, because the Company believed there was value to being associated with these partners that would lead to future revenues to HealthGate from third parties. If the Company had reached a different conclusion it would have yielded materially different results. The valuations of the warrants required certain significant judgments and estimates, including the term, volatility and interest rates that were used in the Black-Scholes valuation model. If different assumptions and estimates had been made the amount capitalized and the related amortization could have been materially different.
Upon adoption of EITF 01-09 on January 1, 2002, HealthGate reviewed its agreements to determine whether the Company's accounting would be impacted. HealthGate determined that it could not reasonably estimate the fair value of the services received from HCA-Information and that, accordingly, the warrant granted to CIS Holdings, Inc. did not meet the criteria in EITF 01-09 for classification as an expense. As a result HealthGate reclassified $179,000 of amortization of marketing and distribution rights relating to the warrant issued to CIS Holdings, Inc. from expense to a reduction in revenue for each of the three months ended June 30, 2002 and 2001 and reclassified amortization of $359,000 relating to this warrant from expense to a reduction in revenue for each of the six months ended June 30, 2002 and 2001.
Identifying transactions that are within the scope of EITF 01-09, and determining whether those transactions meet the criteria for recognition as expense, requires HealthGate to make significant judgments. If HealthGate reached different conclusions, reported revenues could be materially different.
Impairments of Long-Lived Assets. HealthGate periodically evaluates its long-lived assets for potential impairment under Statement of Financial Accounting Standards No.144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"). The Company performs such evaluations when events or changes in circumstance suggest that the carrying value of an asset or group of assets is not recoverable. Indicators of potential impairment include:
Determining whether an indicator of potential impairment exists requires significant judgment on the part of the Company.
If an indicator of potential impairment is believed to exist, the Company tests to determine whether the impairment recognition criterion of SFAS 144 has been met. The Company tests this by preparing a projection of future undiscounted cash flows expected to be generated by the asset, and determining whether those cash flows are less than the carrying amount of the asset. In this assessment, assets are grouped at the lowest level for which cash flows are identifiable and largely independent of
15
cash flows of other asset groups. The projection of expected future cash flows includes the Company's best estimate of all applicable cash inflows from operations, any cash outflows necessary to obtain those cash inflows, and any residual value of the asset. If the projected undiscounted cash flows are less than the carrying amount of the asset or group of assets, an impairment is determined to exist.
Once an impairment is determined to exist, the amount of the impairment loss is measured by the excess of the carrying amount of the asset over its fair value. HealthGate generally estimates the fair value of the asset using a discounted cash flow analysis. In this analysis, the Company discounts expected cash flows using a discount rate that it believes is commensurate with the risks involved. The fair value then becomes the asset's new cost basis.
In evaluating long-lived assets for potential impairment, the Company makes several significant estimates and judgments, including: determining the appropriate grouping of assets at the lowest level for which cash flows are available, estimating future cash flows associated with the asset or group of assets, and determining an appropriate discount rate to use in the analysis. Use of different estimates and judgments could yield materially different results in the Company's analysis, and could result in materially different asset impairment charges.
Non-Cash Expenses
HealthGate recorded deferred compensation of $2,307,000 in 1999, representing the difference between the exercise price of stock options granted and the fair market value of the underlying common stock at the date of grants. The difference is recorded as a reduction of stockholders' equity and is being amortized over the vesting period of the applicable options, typically three years. Of the total deferred compensation amount, approximately $9,000 and $77,000 was amortized during the six months ended June 30, 2002 and 2001, respectively. There are no remaining amounts of deferred compensation as of June 30, 2002.
On November 27, 2001, HealthGate commenced an offer to exchange certain options to purchase shares of its common stock, par value $0.03 per share, upon the terms and subject to the conditions described in the Offer to Exchange dated November 27, 2001, as amended (the "Offer"). Under the Offer, employees (including executive officers) were given the opportunity to elect to cancel outstanding stock options held by them in exchange for an equal number of new options to be granted at a future date. Acceptance of the Offer required the employee to exchange any other options granted to him or her during the six months prior to the commencement of the Offer. The Offer expired on Thursday, December 27, 2001. Pursuant to the terms and conditions described in the Offer, HealthGate accepted for exchange options to purchase 552,290 shares of common stock, which were cancelled on December 28, 2001. On July 8, 2002, HealthGate granted new options to purchase an aggregate of 322,141 shares of common stock in exchange for such tendered options. The exercise price of the new options was equal to the fair market value of HealthGate's common stock on the date of grant. The exchange program was designed to comply with Financial Accounting Standards Board Interpretation No. 44, "Accounting for Certain Transactions Involving Stock Compensation," and Emerging Issues Task Force Issue No. 00-23, "Issues Related to the Accounting for Stock Compensation under APB Opinion No. 25 and FASB Interpretation No. 44," and did not result in any additional compensation charges or variable plan accounting.
In October 1999, HealthGate entered into a three-year strategic alliance agreement with Snap! LLC and Xoom.com, Inc. The rights of Snap! LLC and Xoom.com, Inc. were subsequently assigned to NBCi. Under the original agreement, NBCi was to provide various services to promote HealthGate's name, the www.healthgate.com Web site, enterprise-based CHOICE Web sites and the products and services HealthGate offers. In exchange for the services provided to HealthGate by NBCi during the first year of the agreement, HealthGate paid NBCi a minimum cash fee of $10,000,000 plus a $250,000 production and content integration fee, and in November 1999 HealthGate issued to NBCi 166,666
16
shares of its common stock. The value of these shares was $4,500,000 at the time of issuance, which was recorded as prepaid advertising. The value of 83,333 shares was amortized as sales and marketing expense on a straight-line basis in 2000, and the value of the other 83,333 shares was recognized based on the delivery of advertising impressions in the first year of the agreement. In September 2000, HealthGate amended this agreement. One of the provisions of the revised agreement was that HealthGate agreed to redirect its user traffic from www.healthgate.com to the Health Channel section of NBCi's consumer Internal portal at www.nbci.com so that NBCi could count all user traffic as part of its total user base.
In March 2001, HealthGate further amended its agreement with NBCi. Under the amended agreement, HealthGate issued a warrant to NBCi for the purchase of up to 66,666 shares of HealthGate common stock at $0.5625 per share, the then current market price of HealthGate's stock. The Company ascribed a value of approximately $38,000 to the warrant. This amount was being recognized over the remaining term of the amended agreement. HealthGate was also to pay NBCi $2,100,000 in cash in 2001 and $2,800,000 in cash in 2002, and was to provide content to NBCi through October 2004. In return, NBCi was to feature HealthGate as the anchor tenant on the men's health, women's health and drugs and medications sections of the Health Channel of the NBCi portal through October 2002 and share advertising and sponsorship revenue derived from the co-branded www.healthgate.nbci.com Web site with HealthGate through October 2004.
In June 2001, HealthGate negotiated to end its contract with NBCi. In connection with this termination agreement HealthGate paid NBCi $831,000 during the third quarter of 2001. HealthGate also paid NBCi $592,000 in 2001, under the March 2001 amendment.
NBCi is wholly owned by National Broadcasting Company, a subsidiary of General Electric Company. General Electric Company is a principal stockholder of HealthGate.
Results of Operations
Comparison of the Three Months Ended June 30, 2002 with the Three Months Ended June 30, 2001
Revenue
Total revenue for the three months ended June 30, 2002 decreased by $750,000 or 33% compared to the three months ended June 30, 2001. Substantially all of the revenue in both periods was derived from content services. The revenue decrease is primarily related to the expiration of HealthGate's agreement with Blackwell Science and decreases in revenue under the Company's agreement with GEMS.
In March 2001, HealthGate and HCA-Information amended their Co-Branded CHOICE Web Site Agreement. The term of the amended agreement is from March 2001 to November 2002 and calls for HCA-Information to pay license fees to HealthGate of approximately $1,400,000 in both 2001 and 2002. The amendment significantly reduced the content available on the customized HCA-Information CHOICE Web sites, increased the maximum number of hospitals covered to 330 and eliminated HCA-Information's option to terminate the Agreement on June 1, 2001. Revenue relating to this agreement was $246,000 during each of the three months ended June 30, 2002 and June 30, 2001. In accordance with EITF 01-09, revenue in each period has been reduced by $179,000 related to the reclassification of amortization of marketing and distribution rights from operating expense.
The three months ended June 30, 2002, included revenue of $246,000 (16%) from one customer. The three months ended June 30, 2001 included revenue of $246,000 (11%) from one customer, and related party revenue of $325,000 (14%) from Blackwell Science and $397,000 (18%) from GEMS. HealthGate's agreement with Blackwell Science expired in January 2002.
17
Costs and Expenses
Cost of Revenue. Cost of revenue consists primarily of editorial costs to refresh existing proprietary content and build new proprietary content as well as royalties associated with licensed content, amortization of capitalized content related software projects, and related equipment and software costs. Cost of revenue decreased to $741,000 in the three months ended June 30, 2002 from $838,000 in the three months ended June 30, 2001, due primarily to decreased royalty expenses for licensed content resulting from the replacement of several licensed sources of content with proprietary content and savings for technical and development services resulting from cost containment measures taken throughout 2001 and the first six months of 2002. These decreases were partially offset by increased amortization relating to capitalized software development costs for software placed in service in the second quarter of 2002. As a percentage of total revenue, cost of revenue increased from 37% for the three months ended June 30, 2001 to 49% for the three months ended June 30, 2002.
Research and Development. Research and development expenses consist primarily of salaries and related costs associated with the development and support of the Company's Web-based content enhancement initiatives. Research and development expenses decreased to $605,000 for the three months ended June 30, 2002 from $775,000 for the three months ended June 30, 2001, due primarily to savings in salaries and related costs for technical and development personnel and consultants resulting from cost containment measures taken throughout 2001 and the first six months of 2002. During the three months ended June 30, 2001, software development costs totaling $428,000 were capitalized. These costs began being amortized into cost of revenue over the one-year estimated life of the related software in April 2002. During the three months ended June 30, 2002, approximately $50,000 of software development costs were capitalized. These costs will be amortized into cost of revenue over the one-year estimated life of the related software, once that software is complete and ready for its intended use.
Sales and Marketing. Sales and marketing expenses consist primarily of salaries, commissions, and related costs for sales and marketing personnel, as well as the cost of advertising, marketing and promotional activities. Sales and marketing expenses decreased to $388,000 in the three months ended June 30, 2002 from $2,459,000 in the three months ended June 30, 2001. A significant portion of this decrease was due to expenses relating to the Company's relationship with NBCi of $1,290,000 for the three months ended June 30, 2001. No similar amounts were incurred in the three months ended June 30, 2002 as a result of the termination of the Company's agreement with NBCi in June 2001. This decrease was also due to savings in salaries and related costs and promotional activities resulting from cost containment measures taken in the fourth quarter of 2000 and throughout 2001.
General and Administrative. General and administrative expense consists primarily of salaries and related costs for executive and administrative personnel, as well as legal, accounting and insurance costs. General and administrative expenses decreased to $1,098,000 in the three months ended June 30, 2002 from $1,607,000 in the three months ended June 30, 2001. This decrease primarily relates to savings in salaries and related costs resulting from cost containment measures.
Interest and Other Income, Net. Interest and other income (net) includes interest income, interest expense, and other income. Interest income for the three months ended June 30, 2002 was $24,000 compared to $121,000 for the three months ended June 30, 2001. The decrease is the result of lower invested cash balances and lower interest rates in the current period. Interest expense for the three months ended June 30, 2002 was $6,000 compared to $18,000 for the three months ended June 30, 2001. Other income, net for the three months ended June 30, 2002 was $65,000 compared to $5,000 for the three months ended June 30, 2001.
18
Income Taxes. HealthGate has incurred significant losses for all periods from inception through June 30, 2002. A valuation allowance has been recorded for the entire deferred tax asset as a result of uncertainties regarding the utilization of the asset due to the Company's lack of earnings history.
Comparison of the Six Months Ended June 30, 2002 with the Six Months Ended June 30, 2001
Revenue
Total revenue for the six months ended June 30, 2002 decreased by $1,877,000 or 37% compared to the six months ended June 30, 2001. Substantially all of the revenue in both periods was derived from content services. The revenue decrease is primarily related to the amendment of HealthGate's agreement with HCA-Information, the expiration of the Company's agreement with Blackwell Science and decreases in revenue under the Company's agreement with GEMS.
In March 2001, HealthGate and HCA-Information amended their Co-Branded CHOICE Web Site Agreement. The term of the amended agreement is from March 2001 to November 2002 and calls for HCA-Information to pay license fees to HealthGate of approximately $1,400,000 in both 2001 and 2002. The amendment significantly reduced the content available on the customized HCA-Information CHOICE Web sites, increased the maximum number of hospitals covered to 330 and eliminated HCA-Information's option to terminate the Agreement on June 1, 2001. Revenue relating to this agreement was $491,000 and $791,000 during the six months ended June 30, 2002 and June 30, 2001, respectively. In accordance with EITF 01-09, revenue in each period has been reduced by $359,000 related to the reclassification of amortization of marketing and distribution rights from operating expense.
The six months ended June 30, 2002, included revenue of $491,000 (16%) from one customer and included related party revenue of $116,000 (4%) from Blackwell Science. The six months ended June 30, 2001 included revenue of $791,000 (16%) from one customer, and related party revenue of $926,000 (18%) from Blackwell Science and $839,000 (17%) from GEMS. HealthGate's agreement with Blackwell Science expired in January 2002.
Costs and Expenses
Cost of Revenue. Cost of revenue decreased to $1,214,000 in the six months ended June 30, 2002 from $1,626,000 in the six months ended June 30, 2001, due in part to decreased royalty expenses for licensed content resulting from the replacement of several licensed sources of content with proprietary content. Additionally, cost of revenue for the six months ended June 30, 2001 included $330,000 of amortization of capitalized software development costs for software placed in service in the fourth quarter of 2000 versus amortization of $213,000 in the six months ended June 20, 2002 relating to capitalized software development costs for software placed in service in the second quarter of 2002. As a percentage of total revenue, cost of revenue increased from 32% for the six months ended June 30, 2001 to 38% for the three months ended June 30, 2002.
Research and Development. Research and development expenses decreased to $1,305,000 for the six months ended June 30, 2002 from $1,691,000 for the six months ended June 30, 2001, due primarily to savings in salaries and related costs for technical and development personnel and consultants resulting from cost containment measures taken throughout 2001 and the first six months of 2002. During the six months ended June 30, 2002, software development costs totaling $116,000 were capitalized. These costs will be amortized into cost of revenue over the one-year estimated life of the related software, once that software is complete and ready for its intended use.
Sales and Marketing. Sales and marketing expenses decreased to $898,000 in the six months ended June 30, 2002 from $4,281,000 in the six months ended June 30, 2001. A significant portion of this decrease was due to expenses relating to the Company's relationship with NBCi of $1,620,000 for the
19
six months ended June 30, 2001. No similar amounts were incurred in the six months ended June 30, 2002 as a result of the termination of the Company's agreement with NBCi in June 2001. This decrease was also due to savings in salaries and related costs and promotional activities resulting from cost containment measures throughout 2001 and the first six months of 2002.
General and Administrative. General and administrative expenses decreased to $2,215,000 in the six months ended June 30, 2002 from $3,249,000 in the six months ended June 30, 2001. This decrease primarily relates to savings in salaries and related costs resulting from cost containment measures and realignment of personnel.
Interest and Other Income, Net. Interest income for the six months ended June 30, 2002 was $54,000 compared to $311,000 for the six months ended June 30, 2001. The decrease is the result of lower invested cash balances and lower interest rates in the current period. Interest expense for the six months ended June 30, 2002 was $15,000 compared to $40,000 for the six months ended June 30, 2001. Other income, net for the six months ended June 30, 2002 was $86,000 compared to $5,000 for the six months ended June 30, 2001.
Liquidity and Capital Resources
Since inception and prior to HealthGate's January 2000 initial public offering and concurrent private sale of common stock, operations were primarily financed by the private placement of debt and equity securities. In January 2000, HealthGate completed its initial public offering of common stock and a concurrent private placement of common stock and realized net proceeds of approximately $44,472,000. A portion of the net proceeds was used to repay a $2,000,000 long-term note payable, which was secured by substantially all of the Company's tangible and intangible assets. In addition, in connection with the conversion of then outstanding preferred stock, the Company paid cash for accrued dividends on Series E preferred stock totaling $465,000.
For the six months ended June 30, 2002, cash used in operations was $2,374,000. The Company's net loss of $2,362,000, reduced for non-cash expenses including depreciation and amortization of $1,437,000 and stock-based compensation of $9,000 was a net use of $916,000. Decreases in accounts receivable due to improved collection efforts resulted in an increase in operating cash of $260,000. Increases in prepaid expenses and other assets resulting from pre-payment of an insurance policy resulted in a use of $280,000 of operating cash and decreases in accounts payable, accrued expenses and other long-term liabilities resulted in a use of approximately $626,000 of operating cash. Decreases in deferred revenue resulted in a use of operating cash of $812,000.
For the six months ended June 30, 2001, cash used in operating activities was $3,728,000. The Company's net loss of $5,548,000, reduced for non-cash expenses including depreciation and amortization of $1,807,000 and stock-based compensation of $77,000 was a net use of $3,664,000. During the first six months of 2001, HealthGate's net accounts receivable balance decreased, creating a net increase in operating cash of $1,977,000. This decrease in net accounts receivable was primarily the result of increased collection efforts. Decreases in accounts payable and accrued expenses resulted in a use of $1,802,000 of operating cash. Payments were primarily for liabilities recorded at December 31, 2000. Net changes in all other operating assets and liabilities resulted in a net decrease in operating cash of approximately $239,000 for the six months ended June 30, 2001.
Net cash used in investing activities for the six months ended June 30, 2002 was $509,000, consisting primarily of $393,000 of cash used to acquire certain assets of The Natural Pharmacist and $116,000 used for capitalized software development costs. Net cash provided by investing activities for the six months ended June 30, 2001 was $4,638,000 resulting from proceeds from sales and marketable securities of $4,931,000 and reimbursement of on purchases of fixed assets of $248,000. In the six months ended June 30, 2001, HealthGate used $113,000 to purchase fixed assets and used $428,000 for capitalized software costs.
20
Cash used in financing activities in the six months ended June 30, 2002 was $136,000, which consisted of the payment of obligations under capital lease arrangements. Cash used in financing activities in the six months ended June 30, 2001 was $151,000 which consisted primarily of the payment of obligations under capital lease arrangements.
The following table sets forth HealthGate's contractual obligations by period:
Contractual Obligations |
July 1, 2002 to December 31, 2002 |
2003-2004 |
Thereafter |
Total |
||||
---|---|---|---|---|---|---|---|---|
Operating leases | 475,000 | 1,836,000 | 462,000 | 2,773,000 | ||||
Capital lease obligations | 82,000 | 6,000 | | 88,000 | ||||
Content licensing obligations | 232,000 | 332,000 | | 564,000 |
At June 30, 2002, the Company has $5,570,000 of cash and marketable securities and $871,000 of working capital. The Company has incurred substantial losses and negative cash flows from operations in every fiscal year since inception. In the six months ended June 30, 2002, the Company incurred a net loss of $2,362,000 and negative cash flows from operations of $2,374,000. Additionally, as of June 30, 2002, the Company had an accumulated deficit of $96,093,000.
The Company has taken numerous actions to substantially reduce operating cash outflows. These actions included workforce reductions, terminating the Company's agreement with NBCi, and amending or canceling several content arrangements. If the Company does not achieve its forecasted revenue levels in the future, management is prepared to implement additional cost reductions.
Based on the Company's current forecasted cash flows and its cash and cash equivalents on hand, the Company expects to have sufficient cash to finance its operations through at least the next twelve months. The Company's future beyond the next twelve months is dependent on its ability to achieve break even or positive cash flow, or raise additional financing. There can be no assurance that the Company will be able to do so.
Risk Factors
HealthGate's business involves significant risks and uncertainties. HealthGate operates in a highly competitive and rapidly evolving Internet industry. The risks and uncertainties described below are some of those that HealthGate currently believe may affect the Company.
Failure to generate sufficient revenues, or raise additional capital will have a material adverse effect on HealthGate's long-term viability and its ability to achieve its intended business objectives. At June 30, 2002, the Company had $5,570,000 of cash and cash equivalents and $871,000 of working capital. The Company has incurred substantial losses and negative cash flows from operations in every fiscal period since inception. For the six months ended June 30, 2002, the Company incurred a net loss of $2,362,000 and negative cash flow from operations of $2,374,000. The Company had an accumulated deficit of $96,093,000 at June 30, 2002.
HealthGate has taken numerous actions to substantially reduce operating cash outflows. These actions included workforce reductions, terminating the Company's agreement with NBCi and amending or canceling several content arrangements. Many of these cost savings were made possible through process improvements, development of additional proprietary content and focusing on content sales and services. If the Company does not achieve its forecasted revenue levels in the future, management is prepared to implement additional cost reductions.
Based on the Company's current forecasted cash flows and its cash and marketable securities on hand, the Company expects to have sufficient cash to finance its operations for at least the next twelve months. The Company's future beyond the next twelve months is dependent on its ability to maintain
21
break-even or positive cash flow, or raise additional financing. There can be no assurances that the Company will be able to do so.
The Company's future liquidity and capital requirements will depend upon numerous factors, including the success of existing and new content service offerings, and continued cost containment. The Company currently anticipates its cash resources will be sufficient to meet the presently anticipated working capital, capital expenditures and business expansion requirements for at least the next twelve months. However, the Company may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies, or take advantage of unanticipated opportunities. The Company may be required to raise additional funds through public or private financing, strategic relationships or other arrangements. There can be no assurance that additional funding, if needed, will be available on terms acceptable to the Company, or at all.
The success of the Company's business will depend on HealthGate's ability to sell its content products and services. HealthGate's products and services include licensing content on both an individual resource basis and on a pre-packaged basis. HealthGate licenses access to portions of its content on an individual content resource basis to customers that prefer to choose specific content resources. HealthGate sells its CHOICE Web site products consisting of content and related services on a pre-packaged basis.
A key element of the Company's strategy is to continue sales and licensing into the hospital market as well as to expand sales and licensing into other healthcare markets, such as payors and pharmaceutical companies and to continue entering into agreements with print publishers. If HealthGate is unable to increase sales and licensing, the Company's business prospects, results of operations and the market price of the Company's common stock could be materially adversely affected.
HealthGate's business prospects may suffer if the Company is not able to keep up with the rapid technological developments in the electronic healthcare content industry. The electronic healthcare content industry is characterized by rapid technological developments, evolving industry standards, changes in user and customer requirements and frequent new service and product introductions and enhancements. The introduction of new technology or the emergence of new industry standards and practices could render the Company's systems and, in turn, its products and services, obsolete and unmarketable or require the Company to make significant unanticipated investments in research and development to upgrade its systems in order to maintain the marketability of its products. To be successful, in addition to maintaining the depth and breadth of its content repository, the Company must continue to license or develop leading technology, enhance its existing products and services and respond to emerging industry standards and practices on a timely and cost-effective basis. If the Company is unable to successfully respond to these developments, particularly in light of the rapid technological changes in the electronic healthcare content industry generally and the highly competitive market in which it operates, the Company's business, results of operations and the market price of the Company's common stock could be adversely affected.
HealthGate's ability to implement its Project Intellect strategic initiative will affect the Company's long-term success. HealthGate undertook a project to assign multiple medical indexing vocabularies, such as ICD-9-CM and SNOMED, to selected content assets in the Company's hosted repository. The Company believes that the success of this initiative will strengthen its position in the marketplace by allowing HealthGate to interface with a wide range of clinical and administrative applications, such as scheduling tools, electronic medical records, laboratory results and pharmaceutical systems, and open up additional markets such as insurance companies, managed care and pharmaceutical companies. Although the Company has successfully developed the software and tools necessary to efficiently add the vocabularies to its content repository, there can be no assurance that the Company will be able to
22
successfully market this new initiative. If HealthGate is unsuccessful at marketing the new initiative, then the future success of the Company may be affected.
A significant portion of HealthGate's revenue has historically been derived from a few customers and the loss of any of these customers could adversely affect the Company's business unless the Company finds other significant customers. Historically, HealthGate has generated a substantial portion of its revenue from a few customers. In the six months ended June 30, 2002, one customer, HCA-Information (an affiliate of a HealthGate warrant holder), accounted for 16% of the Company's total revenue.
In March 2001, HealthGate and HCA-Information amended their Co-Branded CHOICE Web Site Agreement. The original agreement initially provided for annual license fees of $3,500,000 to be paid by HCA-Information to HealthGate. The amendment significantly reduced the content that is available on the customized HCA-Information CHOICE Web sites, increased the maximum number of hospitals covered to 330 and eliminated HCA-Information's option to terminate the Agreement on June 1, 2001. The term of the amended agreement is from March 2001 to November 2002 and calls for HCA-Information to pay license fees to HealthGate of $1,417,000 in both 2001 and 2002. HealthGate expects to continue to generate a substantial portion of its revenue in the near future from HCA-Information. In December 2001, HealthGate entered into a beta agreement for Project Intellect with HCAInformation.
Blackwell Science (a stockholder) that has historically accounted for a significant portion of HealthGate's revenue, accounted for 4% of HealthGate's total revenue for the six months ended June 30, 2002. HealthGate's agreement with Blackwell Science terminated on January 31, 2002. HealthGate will not derive significant revenue from Blackwell Science in the remainder of 2002.
HealthGate's agreement with GEMS, as amended, runs through June 2003. Revenues derived under this agreement have been significant prior to 2002. No revenue was recognized from GEMS in the six months ended June 30, 2002 and no significant revenue from GEMS is expected in the remainder 2002.
The loss of HCA-Information as a customer or HealthGate's failure to obtain other significant customers and sources of revenues to replace the revenue previously derived from Blackwell Science and GEMS could adversely affect the Company's business.
HealthGate's quarterly operating results may fluctuate, which could affect the market price of HealthGate's common stock in a manner unrelated to the Company's long-term performance. The Company's quarterly revenue, expenses and operating results may fluctuate in the future, which could affect the market price of the common stock in a manner unrelated to the Company's long-term operating performance. Quarterly fluctuations could result from a number of factors, including:
Although HealthGate does not plan a major increase in spending related to operations, the expense levels are in part based on the Company's expectations concerning future revenue and these expense levels are predominately fixed in the short-term. If the Company has lower revenue than expected, HealthGate may not be able to reduce spending in the short-term in response. Any shortfall in revenue would have a direct impact in HealthGate's results of operations. In this event, the price of the Company's common stock may fall.
HealthGate faces intense competition in licensing its electronic healthcare information products and services and may not be able to compete effectively. The market for healthcare content products and services provided electronically is relatively new, intensely competitive and rapidly changing. With only
23
moderate barriers to entry in a rapidly evolving industry, there are now thousands of content providers offering users healthcare content, products and services, and the Company expects that competition will continue to grow. HealthGate competes, directly and indirectly, for customers, consumers, content and service providers, and acquisition candidates with other electronic healthcare content companies. Some of the Company's competitors may enjoy competitive advantages including: greater resources that can be devoted to the development, promotion and sale of their products and services, longer operating histories, greater brand recognition and larger customer bases.
The performance of HealthGate's Web sites and computer systems is critical to its business and the business will suffer if the Company experiences system failures. The performance of HealthGate's Web sites and computer systems is critical to the Company's reputation and ability to attract and retain users, customers, advertisers and subscribers. HealthGate provides products and services based on sophisticated computer and telecommunications software and systems, which often experience development delays and may contain undetected errors or failures when introduced into the Company's existing systems. HealthGate experienced a minor unscheduled service interruption of approximately four hours in 1998 and a minor unscheduled service interruption of approximately 1 hour in 2002. In April 2001, HealthGate's activePress service experienced an unscheduled service interruption of approximately six hours. The Company cannot guarantee that it will not experience more significant service interruptions in the future. The Company is also dependent upon Web browsers and Internet service providers to provide Internet users access to its Web sites. Many of them have experienced significant outages in the past and could experience outages, delays and other difficulties in the future due to system failures. The Company also depends on certain information providers to deliver information and data feeds to it on a timely basis. HealthGate Web sites could experience disruptions or interruptions in service due to the failure or delay in the transmission or receipt of this information. System errors or failures that cause a significant interruption in the availability of the Company's content or an increase in response time on the Company's Web sites could cause it to lose potential or existing users, customers, advertisers or subscribers and could result in damage to its reputation and brand name or a decline in the Company's stock price.
In March 1999, HealthGate entered into an Internet Data Center Services Agreement with Exodus Communications, Inc. to house all of the Company's central computer facility servers at Exodus's Internet Data Center in Waltham, Massachusetts. In September 2001, Exodus filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code and in December 2001 was purchased by Cable and Wireless. HealthGate does not presently maintain fully redundant systems at separate locations, so the Company's operations depend on Exodus's ability to protect the systems in its data center against damage from fire, power loss, water damage, telecommunications failure, vandalism and similar events. Although Exodus provides comprehensive facilities management services, including human and technical monitoring of all production servers, neither Exodus nor Cable & Wireless guarantees that HealthGate's Internet access will be uninterrupted, error-free or secure.
HealthGate has also developed a disaster recovery plan to respond to system failures. HealthGate cannot guarantee that its disaster recovery plan is capable of being implemented successfully. HealthGate cannot guarantee that the Company's insurance will be adequate to compensate it for all losses that may occur as a result of any system failure.
HealthGate's business prospects may suffer if it is not able to successfully retain key personnel. HealthGate has grown from three employees at the end of 1994 to 41 employees as of June 30, 2002. HealthGate's future success depends on the Company's ability to retain, train, motivate, identify, attract, and hire highly skilled technical, managerial, editorial, sales and customer service personnel. Competition for highly skilled personnel is intense, and the Company cannot guarantee that it will be able to retain or attract skilled personnel.
24
HealthGate may be subject to liability for information retrieved from the Company's content repository. As a publisher and distributor of online information, HealthGate may be subject to third party claims for defamation, negligence, copyright or trademark infringement or other theories based on the nature and content of information supplied by the Company. These types of claims have been brought, sometimes successfully, against online service providers in the past. HealthGate could be subject to liability with respect to content that may be accessible through the Company's content repository or client Web sites. For example, claims could be made against HealthGate if material deemed inappropriate for viewing by children could be accessed through its Web site or if a professional, patient or consumer relies on healthcare information accessed through HealthGate to their detriment. Even if any of the kinds of claims described above do not result in liability to the Company, HealthGate could incur significant costs in investigating and defending against them and in implementing measures to reduce its exposure to this kind of liability. The Company's insurance may not cover potential claims of this type or may not be adequate to cover all costs incurred in defense of potential claims or to indemnify HealthGate for all liability that may be imposed.
HealthGate's business depends on its ability to provide a comprehensive library of healthcare information. A significant portion of HealthGate's content is proprietary. HealthGate licenses the rest of its content from third parties. These licenses are generally non-exclusive, have an initial term of one year and are renewable. In addition, a number of these licenses permit cancellation by the content provider upon 30 to 90 days notice. HealthGate cannot guarantee that it will be able to continue to license its present content or be able to develop or license sufficient additional content to provide a diverse and comprehensive library.
HealthGate's business may be adversely affected if the Company is not able to effectively protect its intellectual property rights. HealthGate regards its trademarks, service marks, copyrights, trade secrets and similar intellectual property as important to its business, and the Company relies upon trademark and copyright law, trade secret protection and confidentiality and/or license agreements with its employees, customers, strategic partners and others to protect its rights in this property. HealthGate has registered the Company's "HealthGate," "HealthGate Data," "CHOICE," "MedGate," "ReADER," "activePress," and its HealthGate logo trademarks in the United States. On February 12, 2002, HealthGate acquired the U.S. registered trademark for "The Natural Pharmacist" along with the trademark registration for "TNP.com". Effective trademark, copyright and trade secret protection may not be available in every country in which HealthGate products and services are distributed or made available through the Internet. Therefore, HealthGate cannot guarantee that the steps it has taken to protect its proprietary rights will be adequate to prevent infringement or misappropriation by third parties or will be adequate under the laws of some foreign countries, which may not protect HealthGate's proprietary rights to the same extent, as do the laws of the United States.
Although HealthGate believes that its proprietary rights do not infringe on the intellectual property rights of others, other parties may assert infringement claims against the Company or claim that the Company has violated a patent or infringed a copyright, trademark or other proprietary rights belonging to them. These claims, even if they are without merit, could result in HealthGate spending a significant amount of time and money to dispose of them. In July 1999, HealthGate received a letter from a company (the "Holder") claiming ownership of a patent that claims exclusive rights to all electronic methods of on-demand remote retrieval of graphic and audiovisual information. The letter asserted that the use of HealthGate's Web site, www.healthgate.com, induces users to infringe the patent. In the letter, the Holder offered to license the patent perpetually and retroactively to HealthGate for a one-time fee of between $50,000 and $150,000 depending upon the number of "hits" per day on the Company's web site. There has been no recent activity on this matter and at this time, HealthGate is unable to predict its outcome.
25
HealthGate's business may be adversely affected if the Company is unable to continue to license software that is necessary for the development of product and service enhancements. HealthGate relies on a variety of technologies that are licensed from third parties, including the Company's database software and Internet server software, which is used in HealthGate's computer network to perform key functions. These third party licenses may not be available to HealthGate on commercially reasonable terms in the future. The loss of or inability to maintain any of these licenses could delay the introduction of software enhancements, interactive tools and other features until equivalent technology could be licensed or developed.
Government regulation of the Internet may result in increased costs of using the Internet, which could adversely affect HealthGate's business. Currently, there are a number of laws that regulate communications or commerce on the Internet. Several telecommunications carriers have petitioned the Federal Communications Commission to regulate Internet service providers and online service providers in a manner similar to long distance telephone carriers and to impose access fees on these providers. Regulation of this type, if imposed, could substantially increase the cost of communicating on the Internet and adversely affect the Company's business, results of operations and the market price of the Company's common stock.
Privacy-related regulation associated with protecting an individual's medical records or other personal identifying information could adversely affect HealthGate's business. User privacy has become an issue both in the United States and abroad. The United States Department of Health and Human Services has recently implemented regulations to protect the privacy of individuals' medical records and health information that may affect the way HealthGate currently does business. Other government agencies have been investigating certain companies regarding their use of their users' personal information. In addition, the European Union (EU) has adopted a directive that imposes restrictions on how companies may use personal data of citizens of EU member states. HealthGate cannot make assurances that current or future regulations imposed domestically or overseas will not adversely affect the Company's business.
As part of the Company's agreements with a few content suppliers, HealthGate maintains a limited amount of confidential information about those users who access certain content sources, such as the user's name, e-mail address and gender. HealthGate has a stringent privacy policy covering this information and maintains facilities and infrastructure designed to keep this information secure. However, a material security breach could damage our reputation or result in liability to the Company. HealthGate could also become liable if confidential information is disclosed inappropriately. Any such action could result in litigation, HealthGate's involvement in which, regardless of the outcome, could require HealthGate to expend significant financial resources. HealthGate could incur additional expenses if new regulations regarding the use of personal information are introduced or if any regulator chooses to investigate HealthGate's privacy practices.
Tax treatment of companies engaged in Internet commerce may adversely affect the Internet industry and HealthGate. Tax authorities on the federal, state, and local levels are currently reviewing the appropriate tax treatment of companies engaged in Internet commerce. New state tax regulations may subject HealthGate to additional state sales, income and other taxes. In November 2001, the federal law that placed a temporary moratorium on certain types of taxation on Internet commerce was extended through November 2003. HealthGate cannot predict the effect of current attempts at taxing or regulating commerce over the Internet. It is also possible that the governments of other states and foreign countries also might attempt to regulate HealthGate's transmission of content. Any new legislation, regulation or application or interpretation of existing laws would likely increase HealthGate's cost of doing business and may adversely affect its results of operations and the market price of the Company's common stock.
26
HealthGate may be subject to liability for claims that the distribution of medical information constitutes practicing medicine over the Internet. States and other licensing and accrediting authorities prohibit the unlicensed practice of medicine. HealthGate does not believe that its publication and distribution of healthcare information online constitutes practicing medicine. However, HealthGate cannot guarantee that one or more states or other governmental bodies will not assert claims contrary to its belief. Any claims of this nature could result in HealthGate spending a significant amount of time and money to defend and dispose of them.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
HealthGate is not subject to any meaningful market risks related to currency, commodity prices or similar matters. HealthGate is sensitive to short-term interest rate fluctuations to the extent that such fluctuations impact the interest income HealthGate receives from its investments. To minimize this risk, HealthGate maintains its portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, other short-term debt securities and money market funds. In general, money market funds are not subject to market-risk because the interest paid on such funds fluctuates with the prevailing interest rate. In addition, HealthGate invests in relatively short-term securities. HealthGate does not use derivative financial instruments in its investment portfolio. HealthGate limits its default risk by purchasing only investment grade securities. As of June 30, 2002, all of HealthGate's investments were in money market funds. Cash and cash equivalents were approximately $5,570,000 at June 30, 2002.
27
Item 4. Submission of Matters to a Vote of Security Holders
HealthGate's Annual Meeting of stockholders was held on June 18, 2002 in Wakefield, Massachusetts.
The vote to elect two persons as Class III Directors of HealthGate was as follows:
|
Number of Shares |
|||
---|---|---|---|---|
Nominee |
For |
Withheld Authority |
||
Edson D. de Castro | 5,224,307 | 20,215 | ||
William S. Reece | 5,224,307 | 20,215 |
Accordingly. Messrs. Reece and de Castro were elected as Class III Directors to serve for a three-year term until the 2005 Annual Meeting of Stockholders and until their successors are elected and qualified. Class I directors (David Friend and William G. Nelson, Ph.D.) whose terms are scheduled to expire at the 2003 Annual Meeting of Stockholders and Class II directors (Gerald E. Bisbee, Jr., Ph.D., Jonathan J.G. Conibear and Thomas O. Pyle) whose terms are scheduled to expire at the 2004 Annual Meeting of Stockholders have terms as directors that continue after the June 2002 Annual Meeting.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
(b) Reports on Form 8-K
No reports on Form 8-K were filed by HealthGate during the three months ended June 30, 2002.
28
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
HEALTHGATE DATA CORP. | ||||
Dated: August 1, 2002 |
By: |
/s/ WILLIAM S. REECE William S. Reece Chairman of the Board of Directors and Chief Executive Officer |
||
Dated: August 1, 2002 |
By: |
/s/ VERONICA ZSOLCSAK Veronica Zsolcsak Chief Financial Officer (Principal Financial Officer) |
29